Compare EDSA & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDSA | OSRH |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.2M |
| IPO Year | N/A | N/A |
| Metric | EDSA | OSRH |
|---|---|---|
| Price | $1.30 | $0.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 33.0K | ★ 2.7M |
| Earning Date | 12-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.45 |
| 52 Week High | $4.49 | $12.54 |
| Indicator | EDSA | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 23.75 | 45.79 |
| Support Level | $1.43 | $0.54 |
| Resistance Level | $1.50 | $0.69 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.59 | 18.30 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.